Ascorbic Acid to Prevent Postreperfusion Syndrome in Liver Transplantation

• Status: Recruiting
• Trial end date: 2023-07-30
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this clinical trial is to test the efficacy of intravenous ascorbic acid in preventing the postreperfusion syndrome in liver transplantation. The main questions it aims to answer are:

• Can intravenous ascorbic acid prevent postreperfusion syndrome in liver transplantation ?

• Can ascorbic acid decrease the incidence of liver graft dysfunction after liver transplantation?

• Can ascorbic acid decreased the incidence of postoperative complications after liver transplantation ?

Participants will receive 1.5 g of intravenous ascorbic acid diluted in 100 ml of saline or 100 ml of saline alone, during the anhepatic phase of liver transplantation before reperfusion of the new graft.

Researchers will compared the incidence of postreperfusion syndrome in both groups.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Universitario Ramon y Cajal
• Treatments: Ascorbic Acid

Criteria

Inclusion Criteria:

• Patients undergoing liver transplantation

Exclusion Criteria:

• Pregnancy

• Allergy to ascorbic acid

• Nephrolithiasis

• Glucose-6-phosphate dehydrogenase (G6PD) deficiency

• Hyperoxaluria

• Hyperuricemia

• Haemochromatosis

• Sickle cell anemia

• Serum Creatinine > 1.2 mg/dl in women and 1.3 mg/dl in men

• Split liver graft

• Acute liver failure

• Living donor liver transplantation

• Controlled donor asystolia

• Treatment with: indinavir, Vitamin B12, Cyclosporine, iron, deferoxamine, disulfiram